Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Spectrum Pharmaceuticals acquires Renazorb(TM) and Renalan(TM) from Altair Nanotechnologies

Abstract:
Spectrum Pharmaceuticals, Inc. has acquired all the patent rights associated with Renazorb(TM) and Renalan(TM) from Altair Nanotechnologies, Inc., a manufacturer of nanomaterials and nano-based products. Spectrum Pharmaceuticals is a biotechnology company focused on Oncology. Both the companies are based in the US.

Spectrum Pharmaceuticals acquires Renazorb(TM) and Renalan(TM) from Altair Nanotechnologies

Irvine, CA | Posted on August 10th, 2009

This agreement amends and restates an existing, limited licensing agreement between Spectrum and Altair, for Renazorb(TM) and Renalan(TM) compound. Spectrum will now have exclusive worldwide rights to Renazorb(TM), Renalan(TM), and any related compounds in any field of use.

Under terms of the agreement, Altair would receive $0.75 million in Spectrum restricted common stock. In addition to the royalty and other payments, Altair was to receive under the prior license agreement. Altair would now receive 10% of any fees Spectrum may receive from the sub-licensing of Renazorb(TM), Renalan(TM), and any related compounds.

Update on June 7, 2006:

Altair announced it would receive 0.1 million shares of Spectrum stock for a milestone payment and an additional 0.04 million shares for product development improvements, with a total approximate value of $0.55 million, following a mutually agreed upon resolution to arbitration proceedings involving the two companies. Altair and Spectrum would continue efforts to move the RenaZorb product technology to market quickly.

Announcement (January 31, 2005):

Spectrum has acquired worldwide exclusive rights to RenaZorb (two second-generation lanthanum-based phosphate binding agents) from Altair. These novel non-aluminum, non-calcium phosphate binders which utilize Altair' proprietary lanthanum nanomaterial technology have the potential to treat hyperphosphatemia, in patients with end-stage renal disease and chronic kidney disease.

Under the terms of the agreement, Spectrum acquired an exclusive worldwide license to develop and commercialize RenaZorb(TM) for all human therapeutic and diagnostic uses. In return, Spectrum would pay to Altair an upfront payment of 0.1 million shares of restricted Spectrum common stock and would make an equity investment of $0.2 million for 38,314 shares of Altair common stock. In addition, Altair would be eligible to receive payments upon achievement of a clinical development and certain regulatory and sales milestones, in addition to royalties on potential net sales.

####

About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), is a biopharmaceutical company that acquires, develops and commercializes a diversified portfolio of oncology and other drug candidates that meet critical health challenges for which there are few other treatment options. The Company’s pipeline includes promising early and late-stage drug candidates with unique formulations and mechanisms of action that address the needs of seriously ill patients, such as at-home chemotherapy and new treatment regimens for refractory disease.

For more information, please click here

Contacts:
Spectrum Pharmaceuticals, Inc.
157 Technology Drive
Irvine, CA 92618
Phone: (949) 788-6700
Fax: (949) 788-6706

Copyright © tradingmarkets.com

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related Links

Spectrum Pharmaceuticals

Related News Press

News and information

Maximum Precision in 3D Printing: New complete solution makes additive manufacturing standard for microfabrication February 26th, 2015

Real-time observation of bond formation by using femtosecond X-ray liquidography February 26th, 2015

Bruker-Sponsored Sixth AFM BioMed Conference Highlights Increasing Impact of AFM in Biological Applications February 26th, 2015

Graphene shows potential as novel anti-cancer therapeutic strategy: University of Manchester scientists have used graphene to target and neutralise cancer stem cells while not harming other cells February 26th, 2015

Investments/IPO's/Splits

Arrowhead to Present at 2015 RBC Capital Markets' Global Healthcare Conference February 17th, 2015

Iran 1st among Islamic Nations in Scientific Production, Nanotechnology February 16th, 2015

Harris & Harris Group Portfolio Company D-Wave Systems Raises an Additional $29 Million (CAD), Closing 2014 Financing at $62 Million (CAD) February 2nd, 2015

Malaysian Nanotechnology Company Nanopac Innovation Ltd. lists on the NSX January 19th, 2015

Nanomedicine

Graphene shows potential as novel anti-cancer therapeutic strategy: University of Manchester scientists have used graphene to target and neutralise cancer stem cells while not harming other cells February 26th, 2015

Cutting-edge technology optimizes cancer therapy with nanomedicine drug combinations: UCLA bioengineers develop platform that offers personalized approach to treatment February 24th, 2015

Optical nanoantennas set the stage for a NEMS lab-on-a-chip revolution February 24th, 2015

Together, nanotechnology and genetic interference may tackle 'untreatable' brain tumors: Tel Aviv University researchers' groundbreaking strategy stops brain tumor cell proliferation with targeted nanoparticles February 24th, 2015

Announcements

Maximum Precision in 3D Printing: New complete solution makes additive manufacturing standard for microfabrication February 26th, 2015

Real-time observation of bond formation by using femtosecond X-ray liquidography February 26th, 2015

Bruker-Sponsored Sixth AFM BioMed Conference Highlights Increasing Impact of AFM in Biological Applications February 26th, 2015

Graphene shows potential as novel anti-cancer therapeutic strategy: University of Manchester scientists have used graphene to target and neutralise cancer stem cells while not harming other cells February 26th, 2015

Patents/IP/Tech Transfer/Licensing

New Paper-like Material Could Boost Electric Vehicle Batteries: Researchers create silicon nanofibers 100 times thinner than human hair for potential applications in batteries for electric cars and personal electronics February 20th, 2015

Nanotech Discoveries Move from Lab to Marketplace with Lintec Deal: Licensing Partnership Brings Together University Technology, New Richardson-Based Facility Directed by Alumni February 9th, 2015

Graphenea granted patent on graphene transfer February 9th, 2015

Toronto-based Environmental Technology Pioneer Green Earth Nano Science Expands in EU February 6th, 2015

Nanobiotechnology

Bacteria network for food: Bacteria connect to each other and exchange nutrients February 23rd, 2015

Building tailor-made DNA nanotubes step by step: New, block-by-block assembly method could pave way for applications in opto-electronics, drug delivery February 23rd, 2015

Better batteries inspired by lowly snail shells: Biological molecules can latch onto nanoscale components and lock them into position to make high performing Li-ion battery electrodes, according to new research presented at the 59th annual meeting of the Biophysical Society February 12th, 2015

DNA 'cage' could improve nanopore technology February 10th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE